Results 71 to 80 of about 14,917 (240)

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes [PDF]

Journal of Clinical Oncology, 2011
Over the last decade, treatment approaches for patients with myelodysplastic syndromes (MDS) have improved significantly. Treatment of MDS is tailored to the specific risk characteristics of the patient. In general, patients are divided into lower- and higher-risk categories.
Guillermo, Garcia-Manero, Pierre, Fenaux
openaire   +2 more sources

Solamargine induces acute myeloid leukemia differentiation through TLR8 activation

VIEW, EarlyView.
SM, a steroidal alkaloid from Solanum nigrum L. has shown anticancer effect on various kinds of human cancer cells, yet its effect on leukemia cells remains unclear. This study examines antileukemic activities of SM in AML cells. Results indicate SM inhibits growth and promotes apoptosis of AML cells.
Qiaoyan Han, Yuting Chen, Zheyi Li, Yonglin Peng, Zhehan Hu, Yuliang Deng, Yanli Fu, Ming Cheng, Sheng Tan, Jing Tian, Xiaodong Zhao, Miao Sun   +11 more
wiley   +1 more source

Real‐life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single‐centre experience

Clinical Case Reports, 2022
We report our experience with venetoclax/hypomethylating agents (Ven/HMA) in 8 AML patients not candidates for intensive CT or refractory/relapsed with limited treatment options. The response rate was 50%.
Alicia Roldán Pérez, Juan Andrés Vázquez Paganini, M. José Penalva Moreno, Eugenio Giménez Mesa, Alba Sara Vilches Moreno, Claudia Nuñez‐Torrón Stock, Regina Herráez García   +6 more
doaj   +1 more source

IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells [PDF]

, 2018
In high-grade serous ovarian cancer (OC), chemotherapy eliminates the majority of tumor cells, leaving behind residual tumors enriched in OC stem cells (OCSC).
Berek, Canino, Fang, Han, Kastan, Paschall, Pasquier, Wang, Wang, Zou, Ørskov   +10 more
core   +1 more source

Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection

Nature Communications, 2019
The development of post-chemotherapy resistance is a significant issue in the management of AML. Here, Caiado et al. suggest that the issue might be circumvented via upfront combination with hypomethylating agents that shape the clonal dynamics and ...
Francisco Caiado, Diogo Maia-Silva, Carolina Jardim, Nina Schmolka, Tânia Carvalho, Cláudia Reforço, Rita Faria, Branka Kolundzija, André E. Simões, Tuncay Baubec, Christopher R. Vakoc, Maria Gomes da Silva, Markus G. Manz, Ton N. Schumacher, Håkan Norell, Bruno Silva-Santos   +15 more
doaj   +1 more source

RSL3 enhances ROS-mediated cell apoptosis of myelodysplastic syndrome cells through MYB/Bcl-2 signaling pathway

Cell Death and Disease
Myelodysplastic syndromes (MDS) are clonal hematopoietic malignancies and seriously threaten people’s health. Current therapies include bone marrow transplantation and several hypomethylating agents.
Li Liu, Chaoying Yang, Lin Zhu, Yanyan Wang, Fuxiang Zheng, Long Liang, Pengfei Cao, Jing Liu, Xu Han, Ji Zhang   +9 more
doaj   +1 more source

Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

Nature Communications, 2019
In acute myeloid leukemia, hypomethylating agents decitabine and azacytidine are used interchangeably. Here, the authors show that the major metabolite of decitabine, but not azacytidine, is subject to SAMHD1 inactivation, highlighting SAMHD1 as a ...
Thomas Oellerich, Constanze Schneider, Dominique Thomas, Kirsten M. Knecht, Olga Buzovetsky, Lars Kaderali, Christoph Schliemann, Hanibal Bohnenberger, Linus Angenendt, Wolfgang Hartmann, Eva Wardelmann, Tamara Rothenburger, Sebastian Mohr, Sebastian Scheich, Federico Comoglio, Anne Wilke, Philipp Ströbel, Hubert Serve, Martin Michaelis, Nerea Ferreirós, Gerd Geisslinger, Yong Xiong, Oliver T. Keppler, Jindrich Cinatl   +23 more
doaj   +1 more source

Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS)

Case Reports in Hematology, 2020
T/myeloid mixed-phenotype acute leukemia not otherwise specified (MPAL NOS) is an uncommon and aggressive leukemia without well-established treatment guidelines, particularly when relapsed.
Heather Klocke, Zhao Ming Dong, Craig O’Brien, Nicholas Burwick, Robert E. Richard, Daniel Y. Wu, Thomas R. Chauncey, Solomon A. Graf   +7 more
doaj   +1 more source

Hypomethylating agents in vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review

British Journal of Haematology, EarlyView.
Summary VEXAS syndrome (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) is an X‐linked, systemic, haemato‐inflammatory syndrome caused by somatic mutations in the UBA1 gene. No standardized treatment guidelines exist, but evidence is emerging that treatment with hypomethylating agents (HMAs) can induce improvement of the inflammatory symptoms,
Fieke W. Hoff, Roochi Trikha, Emma M. Groarke, Bhavisha A. Patel   +3 more
wiley   +1 more source